Af­ter Ver­sa­nis suc­cess, Adi­tum launch­es Celex­or Bio with au­toim­mune drug from Ace­lyrin part­ner In­ma­gene

The biotech li­cens­ing whizzes at Adi­tum Bio, the VC firm from ex-No­var­tis CEO Joe Jimenez and Mark Fish­man, have cre­at­ed their 10th com­pa­ny by nab­bing the rights to a pre­clin­i­cal au­toim­mune drug.

The new start­up, Celex­or Bio, will pay an undis­closed up­front and up to $287 mil­lion in biobucks to San Diego-based In­ma­gene Bio­phar­ma­ceu­ti­cals, which will al­so get an eq­ui­ty stake in the new biotech and po­ten­tial roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER